"""
Question: 1101 

Evidence: Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women identified during acute HIV-1 infection in Durban, South Africa, through twice-weekly screening of high-risk participants. All raw HIV sequence data that support the findings of this study have been deposited in GenBank (accession numbers MK643536–MK643827).

Rationale: The abstract states they generated new longitudinal sequencing data from four acutely infected women, and the Data availability section confirms deposition of the raw sequence data to GenBank, indicating these are newly generated, previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women identified during acute HIV-1 infection. All raw HIV sequence data that support the findings of this study have been deposited in GenBank (accession numbers MK643536–MK643827).

Rationale: The paper explicitly reports generation of near-full-length HIV-1 DNA sequences and provides GenBank accession numbers, demonstrating that HIV sequences are reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Total PBMC collected from each patient at each time point were independently subjected to DNA extraction using DNeasy Blood & Tissue Kits (QIAGEN). All PCR amplicons detectable by gel electrophoresis were subjected to Illumina library preparation via shearing-based adaptor-ligation-based technology and MiSeq sequencing, followed by de novo assembly of the resulting small reads.

Rationale: The methods describe direct extraction and sequencing of HIV-1 DNA from PBMCs without any mention of culturing viruses or passaging them in vitro; thus, no in vitro passage experiments were performed.

Answer: No
"""

"""
Question: 1104 

Evidence: In this study, we provide a comprehensive evaluation of early HIV-1 DNA genome landscapes during the 1st year of infection. All PCR amplicons detectable by gel electrophoresis were subjected to Illumina library preparation and MiSeq sequencing, followed by de novo assembly.

Rationale: The study focuses on genotypic near-full-length sequencing of proviral DNA; there is no description of phenotypic antiretroviral susceptibility testing or in vitro drug susceptibility assays.

Answer: No
"""

"""
Question: 2101 

Evidence: All raw HIV sequence data that support the findings of this study have been deposited in GenBank (accession numbers MK643536–MK643827). The authors declare that all data supporting the findings of this study are available within the paper and its Supplementary Information files.

Rationale: The Data availability section explicitly provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women identified during acute HIV-1 infection in Durban, South Africa. All raw HIV sequence data that support the findings of this study have been deposited in GenBank (accession numbers MK643536–MK643827).

Rationale: The sequences are derived from acutely infected women (clinical samples), not laboratory strains; the paper provides accession numbers for these clinical isolates.

Answer: Yes
"""

"""
Question: 2103 

Evidence: All raw HIV sequence data that support the findings of this study have been deposited in GenBank (accession numbers MK643536–MK643827). Data underlying all figures are reported in Supplementary Tables 2, 3, and 4.

Rationale: The accession number range is explicitly provided in the Data availability section.

Answer: MK643536–MK643827
"""

"""
Question: 2202 

Evidence: Fig. 5 Genetic variations among intact HIV-1 DNA genomes detected in this study. Los Alamos HIV Sequence Database highlighter plots of all intact viral genomes derived in this study across all time points. Data underlying all figures are reported in Supplementary Tables 2, 3, and 4.

Rationale: The paper visualizes mutations using highlighter plots and reports summary data in supplementary tables, but does not provide lists of specific mutations for each individual sequenced isolate as tabulated per-sample mutation lists.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV-1 DNA sequence diversity and evolution during acute subtype C infection. Current HIV-1 antiretroviral treatment successfully controls viral replication and has transformed HIV-infection from a fatal illness to a manageable chronic condition.

Rationale: The title and text repeatedly refer to HIV-1, indicating the species studied is HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women. Despite our limitations in sample size and sampling depth, this study is, to our knowledge, the first to longitudinally quantify population evolutionary dynamics of HIV-1 DNA species in hyperacute HIV-1 infection, specifically in the context of the HIV-1 clade C epidemic in sub-Saharan Africa.

Rationale: The abstract and discussion explicitly state the viruses are subtype C (clade C).

Answer: Subtype C (clade C)
"""

"""
Question: 2303 

Evidence: Our near-full-length viral genome sequencing method involved PCR amplification spanning HXB2 coordinates 638 (Lys tRNA primer binding site) to 9632 (3′LTR R repeat). In total, we evaluated 67 distinct epitopes ... spanning all HIV proteins from Gag to Nef. Presence of premature stop codons and/or insertions or deletions in any of HIV's essential genes gag, pol or env was assessed.

Rationale: The sequencing covered near-full-length genomes across all genes from Gag to Nef, including gag, pol, env and other genes in that range.

Answer: Near full-length HIV-1 genomes including gag, pol, env and other genes from Gag to Nef (HXB2 638–9632)
"""

"""
Question: 2304 

Evidence: Presence of premature stop codons and/or insertions or deletions in any of HIV's essential genes gag, pol or env was assessed. Our near-full-length viral genome sequencing method involved PCR amplification spanning HXB2 coordinates 638 to 9632.

Rationale: Because pol lies within the sequenced near-full-length region and was explicitly analyzed for defects, the paper reports results that include HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women identified during acute HIV-1 infection in Durban, South Africa. The FRESH cohort is an observational, prospective cohort launched in 2012 in Umlazi, Durban, South Africa.

Rationale: The sampled individuals were from the FRESH cohort in Durban, South Africa.

Answer: Durban, South Africa
"""

"""
Question: 2402 

Evidence: The FRESH cohort is an observational, prospective cohort launched in 2012 in Umlazi, Durban, South Africa. As of August 2018, 946 women were enrolled; 72 were identified with acute HIV-1 infection.

Rationale: Although the cohort timeline is given (launched in 2012, status as of 2018), the specific years of sample collection for the sequenced samples are not explicitly stated.

Answer: NA
"""

"""
Question: 2502 

Evidence: All PCR amplicons detectable by gel electrophoresis were subjected to Illumina library preparation via shearing-based adaptor-ligation-based technology and MiSeq sequencing. MiSeq (Illumina) deep sequencing and viral bioinformatics were used.

Rationale: Sequencing was performed using Illumina MiSeq (NGS), not Sanger sequencing.

Answer: No
"""

"""
Question: 2503 

Evidence: All PCR amplicons ... were subjected to Illumina library preparation ... and MiSeq sequencing, followed by de novo assembly of the resulting small reads. MiSeq (Illumina) deep sequencing and viral bioinformatics were used.

Rationale: The use of Illumina MiSeq indicates next-generation sequencing was used.

Answer: Yes
"""

"""
Question: 2504 

Evidence: Total PBMC collected from each patient ... were subjected to DNA extraction ... followed by HIV-1 near-full-genome amplification using a single-amplicon nested PCR approach. All PCR amplicons ... were subjected to Illumina library preparation via shearing-based adaptor-ligation-based technology and MiSeq sequencing.

Rationale: The workflow used PCR amplification and library preparation for NGS without mention of cloning viral genomes into plasmids; thus samples were not cloned prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Here, we use near-full-length, single genome next-generation sequencing. Extracted DNA was diluted ... so that the statistical probability of one HIV-1 genome template per PCR reaction was 85.7%.

Rationale: The study performed single-genome amplification (SGA) by diluting DNA to achieve single-template reactions.

Answer: Yes
"""

"""
Question: 2506 

Evidence: HIV-1 near-full-genome amplification used a single-amplicon nested PCR approach. All PCR amplicons were prepared for Illumina sequencing via adaptor-ligation, with no mention of cloning into vectors.

Rationale: There is no description of molecular cloning of the viral genomes; the approach is PCR-based SGA and NGS.

Answer: No
"""

"""
Question: 2601 

Evidence: Total PBMC collected from each patient at each time point were independently subjected to DNA extraction ... followed by HIV-1 near-full-genome amplification. Plasma HIV-1 RNA was first detectable, whereas Pt 4 remained untreated for the entire follow-up period, but no plasma sequencing is described.

Rationale: The sequencing was performed on PBMC-derived DNA; while plasma viral loads were measured, there is no report of plasma virus sequencing.

Answer: No
"""

"""
Question: 2602 

Evidence: We performed single-genome, near full-length HIV-1 DNA sequencing using PBMCs from three chronically-infected patients. Total PBMC collected from each patient ... were subjected to DNA extraction ... followed by HIV-1 near-full-genome amplification.

Rationale: The methods and comparative analysis explicitly state sequencing was done from PBMC-derived DNA.

Answer: Yes
"""

"""
Question: 2603 

Evidence: Total PBMC ... were subjected to DNA extraction and sequencing. The paper reports plasma HIV-1 RNA measurements but does not describe plasma virus sequencing.

Rationale: No plasma HIV sequencing was reported; therefore, the number of plasma virus sequencing samples is zero.

Answer: 0
"""

"""
Question: 2604 

Evidence: Overall, this study collected a total of 292 HIV-1 DNA sequences in all four patients sequentially sampled over a 1-year follow-up period. PBMCs were collected at weekly intervals for a month, then every 2 weeks for 2 months and monthly thereafter for 1-year post infection.

Rationale: Although the number of sequences and the sampling schedule are given, the exact number of PBMC samples subjected to sequencing is not specified.

Answer: NA
"""

"""
Question: 2605 

Evidence: All four patients had detectable viremia at one point during the study. Both untreated patients (Pt 2 and Pt 4) demonstrated a spontaneous graduate 2-log decrease of plasma viral load over 1 year.

Rationale: The presence of detectable viremia indicates active HIV replication in these individuals when samples were obtained.

Answer: Yes
"""

"""
Question: 2606 

Evidence: We provide a longitudinal evaluation of HIV-1 DNA sequences in four subtype C HIV-1-infected individuals identified at stages II and V of acute infection. Our near-full-length viral genome sequencing method involved PCR amplification ... and therefore could theoretically amplify both episomal 2-LTR HIV-1 DNA and integrated proviral genomes.

Rationale: Sequencing targeted HIV-1 DNA from PBMCs, which includes integrated proviral DNA (reservoir) and possibly episomal forms, indicating sequences were obtained from the proviral DNA reservoir.

Answer: Yes
"""

"""
Question: 2701 

Evidence: The FRESH cohort is an observational, prospective cohort launched in 2012 in Umlazi, Durban, South Africa where high-risk HIV-negative women aged 18–23 were recruited. Four female individuals identified in primary HIV-1 infection were ... selected for this study.

Rationale: Participants were adult women aged 18–23; no infants or children were involved.

Answer: No
"""

"""
Question: 2702 

Evidence: The FRESH cohort is an observational, prospective cohort. Following detection of acute HIV-1 infections, PBMCs were collected ... and individuals were offered to start antiretroviral treatment immediately.

Rationale: The study is described as an observational cohort rather than a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: The FRESH cohort is an observational, prospective cohort. No participants were recruited for this specific study; banked, cryopreserved PBMC samples were used.

Rationale: Because it is an observational cohort and not a clinical trial, not all individuals (indeed none) were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: Four female individuals identified in primary HIV-1 infection were ... selected for this study. For comparative purposes, we performed single-genome, near full-length HIV-1 DNA sequencing using PBMCs from three chronically-infected patients.

Rationale: Four acute cases plus three chronic comparators equals seven individuals with sequencing.

Answer: 7
"""

"""
Question: 3102 

Evidence: Four female individuals ... were ... selected for this study to each represent a unique clinical course ... and were longitudinally followed. For comparative purposes, we performed single-genome, near full-length HIV-1 DNA sequencing using PBMCs from three chronically-infected patients.

Rationale: The paper indicates that all four acute participants and three chronic comparators underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Pt 2 remained untreated according to the treatment guidelines at the time of diagnosis for the entire follow-up period of 328 days. Pt 4 remained untreated for the entire follow-up period of 332 days.

Rationale: Two individuals were ART-naive during follow-up, and the paper reports their sequences.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Pt 1 immediately initiated antiretroviral therapy (tenofovir, emtricitabine, efavirenz, raltegravir) after first detection of HIV-1 plasma viremia. Pt 3 immediately received antiretroviral treatment (tenofovir, emtricitabine, efavirenz) when plasma HIV-1 RNA was first detectable.

Rationale: The paper reports sequences from individuals who received ART, including those started immediately after detection and three chronic patients sequenced shortly after therapy initiation.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Pt 2 and Pt 4 remained untreated for the entire follow-up period. Pt 1 and Pt 3 immediately received antiretroviral therapy when viremia was detected.

Rationale: The study includes both ART-naive and ART-experienced individuals with reported sequences.

Answer: Yes
"""

"""
Question: 4104 

Evidence: Pt 2 remained untreated ... for 328 days. Pt 4 remained untreated for the entire follow-up period of 332 days.

Rationale: Two individuals were ART-naive; the study reports sequences from them.

Answer: 2
"""

"""
Question: 4105 

Evidence: Pt 1 immediately initiated antiretroviral therapy (tenofovir, emtricitabine, efavirenz, raltegravir) ... with raltegravir withdrawn 90 days after viral suppression. For comparative purposes, we performed ... sequencing using PBMCs from three chronically-infected patients who ... underwent cell sampling at 18, 70, and 182 days after treatment onset.

Rationale: Detailed ART regimens and changes are provided for Pt 1 and Pt 3, but for the three chronic patients only timing relative to treatment onset is provided without regimen specifics; hence complete ART histories are not provided for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: In this study, we provide a comprehensive evaluation of early HIV-1 DNA genome landscapes during the 1st year of infection. The paper focuses on sequencing and genotypic characterization of proviral DNA and does not present population-level prevalence estimates of transmitted drug resistance.

Rationale: There are no sections reporting prevalence metrics of transmitted resistance; the study design is not a surveillance of TDR but a longitudinal genomic analysis in a small cohort.

Answer: No
"""

"""
Question: 4202 

Evidence: The study describes longitudinal genotypic evolution and intact/defective proviral compositions in four acutely infected individuals. No analyses or statistics on the prevalence of pretreatment HIV drug resistance are presented.

Rationale: The paper does not include prevalence data for pretreatment resistance; it focuses on within-host proviral genotypes.

Answer: No
"""

"""
Question: 4301 

Evidence: Pt 1 immediately initiated antiretroviral therapy (tenofovir, emtricitabine, efavirenz, raltegravir). Pt 3 immediately received antiretroviral treatment (tenofovir, emtricitabine, efavirenz).

Rationale: These regimens include NRTIs (tenofovir, emtricitabine), an NNRTI (efavirenz), and an INSTI (raltegravir, in Pt 1).

Answer: NRTIs, NNRTIs, and INSTIs
"""

"""
Question: 4302 

Evidence: Pt 1 immediately initiated antiretroviral therapy ... raltegravir. In Pt 1, whose regimen contained raltegravir from the beginning of the antiretroviral treatment initiation, a genome-intact provirus ... translated into Y143H, an integrase inhibitor-associated resistance mutation.

Rationale: Raltegravir is an integrase inhibitor; thus, the paper reports individuals who received an INSTI.

Answer: Yes
"""

"""
Question: 4303 

Evidence: Pt 1 regimen: tenofovir, emtricitabine, efavirenz, raltegravir. Pt 3 regimen: tenofovir, emtricitabine, efavirenz.

Rationale: No protease inhibitors (e.g., darunavir, lopinavir) are listed among the drugs received by any individual.

Answer: No
"""

"""
Question: 4304 

Evidence: Pt 1 immediately initiated antiretroviral therapy (tenofovir, emtricitabine, efavirenz, raltegravir), with raltegravir withdrawn 90 days after viral suppression. Pt 3 immediately received antiretroviral treatment (tenofovir, emtricitabine, efavirenz), whereas Pt 2 and Pt 4 remained untreated.

Rationale: Treatment status and regimens differed among individuals; therefore, not all received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Pt 1 immediately initiated antiretroviral therapy ... including raltegravir. In Pt 1, whose regimen contained raltegravir from the beginning ... an integrase inhibitor-associated resistance mutation was observed.

Rationale: At least one individual (Pt 1) received an INSTI (raltegravir), so not all individuals were INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: Pt 1 immediately initiated antiretroviral therapy ... with raltegravir withdrawn 90 days after viral suppression. Pt 3 immediately received antiretroviral treatment (tenofovir, emtricitabine, efavirenz).

Rationale: Only Pt 1 is described as having a regimen change (withdrawal of raltegravir), meaning more than one ART regimen; others either remained untreated or on a single regimen.

Answer: 1
"""

"""
Question: 4404 

Evidence: Pt 1 had raltegravir withdrawn 90 days after viral suppression, indicating one regimen change. No other regimen changes are reported for the remaining individuals.

Rationale: There is no evidence that any individual received more than two regimens.

Answer: 0
"""

"""
Question: 4405 

Evidence: Pt 1 had a regimen change (raltegravir withdrawn). Pt 3 stayed on a single regimen, and Pt 2 and Pt 4 remained untreated.

Rationale: Individuals clearly did not receive the same number of ART regimens given the presence of untreated participants and a regimen change in Pt 1.

Answer: No
"""

"""
Question: 4406 

Evidence: Pt 2 and Pt 4 remained untreated for the entire follow-up period. Pt 1 had raltegravir withdrawn 90 days after suppression, implying more than one regimen.

Rationale: Not all individuals received one ART regimen; some received none and one received more than one.

Answer: No
"""

"""
Question: 4501 

Evidence: Pt 1 immediately initiated antiretroviral therapy (tenofovir, emtricitabine, efavirenz, raltegravir). Pt 3 immediately received antiretroviral treatment (tenofovir, emtricitabine, efavirenz).

Rationale: Dolutegravir is not mentioned among the drugs received; only raltegravir (an INSTI) is listed.

Answer: 0
"""

"""
Question: 4502 

Evidence: Pt 1 regimen: tenofovir, emtricitabine, efavirenz, raltegravir. Pt 3 regimen: tenofovir, emtricitabine, efavirenz.

Rationale: Darunavir (a protease inhibitor) is not listed among any individual’s medications.

Answer: 0
"""

"""
Question: 5101 

Evidence: In Pt 1, whose regimen contained raltegravir from the beginning of the antiretroviral treatment initiation, a genome-intact provirus harboring a single-base substitution at 1-month post-detection translated into Y143H, an integrase inhibitor-associated resistance mutation. No other drug resistance mutations are reported for other individuals.

Rationale: Only Pt 1 is reported to have developed a recognized drug resistance mutation (INSTI-resistance Y143H).

Answer: 1
"""

"""
Question: 5102 

Evidence: In Pt 1, ... a genome-intact provirus ... translated into Y143H, an integrase inhibitor-associated resistance mutation. No other INSTI-resistance mutations are described in the other participants.

Rationale: Only one individual (Pt 1) is reported with an INSTI-resistance mutation.

Answer: 1
"""

"""
Question: 5103 

Evidence: The reported resistance finding was Y143H in integrase. There is no mention of mutations associated with tenofovir disoproxil fumarate (TDF) resistance.

Rationale: The paper does not report any TDF/NRTI resistance-associated mutations.

Answer: 0
"""

"""
Question: 5104 

Evidence: In Pt 1, ... a genome-intact provirus ... translated into Y143H, an integrase inhibitor-associated resistance mutation. Interestingly, in Pt 1, whose regimen contained raltegravir ... Y143H was observed.

Rationale: The specific INSTI-resistance mutation reported is Y143H.

Answer: Y143H
"""

"""
Question: 6101 

Evidence: In this study, we provide a comprehensive evaluation of early HIV-1 DNA genome landscapes during the 1st year of infection. All PCR amplicons ... were subjected to Illumina ... MiSeq sequencing, followed by de novo assembly.

Rationale: The study describes genotypic sequencing and bioinformatics; it does not describe any phenotypic susceptibility testing methods.

Answer: No
"""

"""
Question: 6102 

Evidence: The paper details sequencing and genetic analyses but does not present any IC50 or IC90 measurements. All PCR amplicons ... were subjected to Illumina ... MiSeq sequencing.

Rationale: No inhibitory concentration values are reported.

Answer: No
"""

"""
Question: 6103 

Evidence: The study focuses on sequence-based analyses, intact/defective genome characterization, and CTL epitope diversity. No phenotypic susceptibility or fold-change IC50 data are presented.

Rationale: There is no mention of IC50 fold change values.

Answer: No
"""

"""
Question: 6104 

Evidence: All PCR amplicons ... were subjected to Illumina ... MiSeq sequencing, followed by de novo assembly. The Methods detail bioinformatic pipelines for sequence analysis but no phenotypic assay procedures.

Rationale: No phenotypic susceptibility assay was used or reported.

Answer: NA
"""

"""
Question: 6105 

Evidence: The paper evaluates intact vs. defective proviruses and sequence diversity. There is no section reporting in vitro replication capacity measurements.

Rationale: Replication capacity data are not included.

Answer: No
"""

"""
Question: 6106 

Evidence: The paper reports no phenotypic susceptibility testing. The only drug-related finding is a genotypic integrase resistance mutation (Y143H) detected in one participant.

Rationale: Since no phenotypic susceptibility assays were performed, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Here, we use near-full-length, single genome next-generation sequencing ... in four women identified during acute HIV-1 infection. Total PBMC ... were subjected to DNA extraction ... followed by HIV-1 near-full-genome amplification using a single-amplicon nested PCR approach.

Rationale: The isolates are natural patient-derived sequences; there is no description of site-directed mutagenesis.

Answer: No
"""

"""
Question: 7102 

Evidence: Total PBMC ... were subjected to DNA extraction ... followed by near-full-genome amplification and MiSeq sequencing. The study does not describe any in vitro culture or serial passaging of viruses.

Rationale: No in vitro passage experiments are reported.

Answer: No
"""